Partial
Partially Aligned
Patient Risk:
Low
Summary
The response includes several label-supported clinical and mechanism-of-action statements (indication, injectable/subcutaneous use, CGRP targeting, and migraine prevention) but adds multiple pay/pricing and copay/formulary/biosimilar statements that are not supported by the provided FDA label excerpts, preventing strong alignment.
Category Scores
Accurate Statements
Aimovig is a prescription medicine used to prevent migraine in adults.
Indications and Usage: “AIMOVIG is indicated for the preventive treatment of migraine in adults.” (Section 1)
Aimovig is an injectable therapy.
Dosage and Administration: “70 mg injected subcutaneously once monthly… 140 mg injected subcutaneously once monthly.” (Sections 2.1–2.2)
Aimovig targets the CGRP pathway.
Clinical Pharmacology: “binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.” (Section 12.1)
Aimovig helps reduce the frequency of migraine attacks.
Clinical Studies: evaluated “as a preventive treatment of episodic or chronic migraine…” (Section 14)
Unsupported Statements
Aimovig pricing can vary by country, pharmacy, insurance plan, and whether a patient is paying cash or using coverage.
No pricing, country, pharmacy, insurance, cash-pay, or coverage statements are present in the provided label excerpts.
Insurance formulary placement and prior authorization requirements can affect what patients pay for Aimovig.
No formulary/prior authorization/patient cost statements are present in the provided label excerpts.
Copay assistance programs (if available) can affect what patients pay for Aimovig.
No copay assistance statements are present in the provided label excerpts.
Whether a biosimilar or alternative is available in a market can affect what patients pay for Aimovig.
No biosimilar/alternative availability or market-driven pricing statements are present in the provided label excerpts.
Contract pricing changes between insurers and pharmacies can affect what patients pay for Aimovig.
No contract pricing statements are present in the provided label excerpts.
Prices often fall when exclusivity ends and competition increases.
No exclusivity/competition pricing trend statements are present in the provided label excerpts.
DrugPatentWatch.com tracks patent-related timelines for medicines.
No information about DrugPatentWatch.com or patent-timeline tracking is present in the provided label excerpts.
Contradictions
Low
AI Statement
Aimovig is an injectable therapy.
Label Reference
Label supports subcutaneous injection (“for subcutaneous use only.” Sections 2.2).
Important Omissions
Dose details (70 mg vs 140 mg monthly) were not stated in the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported content is primarily about pricing/access rather than clinical safety. The only dosing-related omission is not safety-critical for this audit scope, and no contraindication/warning claims were made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple non-label-supported statements about pricing, insurance/cost-sharing mechanics, and patent-tracking sources were included.
Suggested Improvement
Limit claims to label-supported content for clinical information and mechanism. Remove or clearly separate non-label business/pricing statements since they are not present in the provided FDA label excerpts. If dosing is mentioned, include the label-supported subcutaneous monthly dosing options (70 mg and possibly 140 mg monthly) and specify “subcutaneous use only.”